Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer

Cancer Letters

Volumn 381, Issue 1, 2016, Pages 96-103

  Roh, Jong Lyel ^a   Kim, Eun Hye ^a   Jang, Hye Jin ^a   Park, Jin Young ^a   Shin, Daiha ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Cisplatin resistance; Cystine glutamate antiporter; Ferroptosis; Head and neck cancer; Lipid reactive oxygen species

Indexed keywords

ANTIPORTER; CISPLATIN; CYSTINE; ERASTIN; GLUTAMIC ACID; PROTEIN INHIBITOR; REACTIVE OXYGEN METABOLITE; SALAZOSULFAPYRIDINE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; AMINO ACID TRANSPORTER; ANTINEOPLASTIC AGENT; GLUTAMINE; GLUTATHIONE; PIPERAZINE DERIVATIVE; SLC7A11 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL DEATH; CELL VIABILITY; CONDITIONED MEDIUM; CONTROLLED STUDY; DRUG CYTOTOXICITY; FERROPTOSIS; GENE SILENCING; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID STORAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; HEAD AND NECK NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

AMINO ACID TRANSPORT SYSTEM Y+; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CISPLATIN; CYSTINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GLUTAMINE; GLUTATHIONE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MICE, INBRED BALB C; MICE, NUDE; PIPERAZINES; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; SULFASALAZINE; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84979872952     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.07.035     Document Type: Article

References (40)

1. [1] Reed, E., Cisplatin, carboplatin, and oxaliplatin. Chabner, B.A., Longo, D.L., (eds.) Cancer Chemotherapy and Biotherapy: Principles and Practice, 2006, Lippincott, Williams, & Wilkins, Philadelphia, PA, 332–343.
2. [2] WHO Model List of Essential Medicines, 19 List. http://www.who.int/medicines/publications/essentialmedicines/en/, 2015.
3. [3] Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis, 5, 2014 e1257.
4. [4] Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics. CA Cancer J. Clin 65:2015 (2012), 87–108.
5. [5] Haddad, R.I., Shin, D.M., Recent advances in head and neck cancer. N. Engl. J. Med 359 (2008), 1143–1154.
6. [6] Kong, M., Hong, S.E., Tumor regression patterns based on follow-up duration in patients with head and neck squamous cell carcinoma treated with radiotherapy or chemoradiotherapy. Clin. Exp. Otorhinolaryngol 8 (2015), 416–421.
7. [7] Petrelli, F., Coinu, A., Riboldi, V., Borgonovo, K., Ghilardi, M., Cabiddu, M., et al. Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies. Oral Oncol 50 (2014), 1041–1048.
8. [8] Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., et al. Molecular mechanisms of cisplatin resistance. Oncogene 31 (2012), 1869–1883.
9. [9] Amable, L., Cisplatin resistance and opportunities for precision medicine. Pharmacol. Res 106 (2016), 27–36.
10. [10] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
11. [11] Conrad, M., Angeli, J.P., Vandenabeele, P., Stockwell, B.R., Regulated necrosis: disease relevance and therapeutic opportunities. Nat. Rev. Drug Discov 15 (2016), 348–366.
12. [12] Dixon, S.J., Lemberg, K.M., Lamprecht, M.R., Skouta, R., Zaitsev, E.M., Gleason, C.E., et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149 (2012), 1060–1072.
13. [13] Yang, W.S., Stockwell, B.R., Ferroptosis: death by lipid peroxidation. Trends Cell Biol 26 (2016), 165–176.
14. [14] Xie, Y., Hou, W., Song, X., Yu, Y., Huang, J., Sun, X., et al. Ferroptosis: process and function. Cell Death Differ 23 (2016), 369–379.
15. [15] Sleire, L., Skeie, B.S., Netland, I.A., Forde, H.E., Dodoo, E., Selheim, F., et al. Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc-, leading to glutathione depletion. Oncogene 34 (2015), 5951–5959.
16. [16] Drayton, R.M., Dudziec, E., Peter, S., Bertz, S., Hartmann, A., Bryant, H.E., et al. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin. Cancer Res 20 (2014), 1990–2000.
17. [17] Guo, W., Zhao, Y., Zhang, Z., Tan, N., Zhao, F., Ge, C., et al. Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma. Cancer Lett 312 (2011), 55–61.
18. [18] Guan, J., Lo, M., Dockery, P., Mahon, S., Karp, C.M., Buckley, A.R., et al. The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. Cancer Chemother. Pharmacol 64 (2009), 463–472.
19. [19] Ma, M.Z., Chen, G., Wang, P., Lu, W.H., Zhu, C.F., Song, M., et al. Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism. Cancer Lett 368 (2015), 88–96.
20. [20] Ye, P., Mimura, J., Okada, T., Sato, H., Liu, T., Maruyama, A., et al. Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition. Mol. Cell. Biol 34 (2014), 3421–3434.
21. [21] Kim, S.Y., Chu, K.C., Lee, H.R., Lee, K.S., Carey, T.E., Establishment and characterization of nine new head and neck cancer cell lines. Acta Otolaryngol 117 (1997), 775–784.
22. [22] Nakamura, M., Nakatani, K., Uzawa, K., Ono, K., Uesugi, H., Ogawara, K., et al. Establishment and characterization of a cisplatin-resistant oral squamous cell carcinoma cell line, H-1R. Oncol. Rep 14 (2005), 1281–1286.
23. [23] Chou, T.C., Drug combination studies and their synergy quantification using the Chou–Talalay method. Cancer Res 70 (2010), 440–446.
24. [24] Gao, M., Monian, P., Quadri, N., Ramasamy, R., Jiang, X., Glutaminolysis and transferrin regulate ferroptosis. Mol. Cell 59 (2015), 298–308.
25. [25] Bauckman, K.A., Haller, E., Flores, I., Nanjundan, M., Iron modulates cell survival in a Ras- and MAPK-dependent manner in ovarian cells. Cell Death Dis, 4, 2013 e592.
26. [26] Dixon, S.J., Stockwell, B.R., The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol 10 (2014), 9–17.
27. [27] Murphy, T.H., Miyamoto, M., Sastre, A., Schnaar, R.L., Coyle, J.T., Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron 2 (1989), 1547–1558.
28. [28] Gorrini, C., Harris, I.S., Mak, T.W., Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov 12 (2013), 931–947.
29. [29] Sato, H., Tamba, M., Ishii, T., Bannai, S., Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J. Biol. Chem 274 (1999), 11455–11458.
30. [30] Huang, Y., Dai, Z., Barbacioru, C., Sadee, W., Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res 65 (2005), 7446–7454.
31. [31] Robert, S.M., Buckingham, S.C., Campbell, S.L., Robel, S., Holt, K.T., Ogunrinu-Babarinde, T., et al. SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma. Sci. Transl. Med, 7, 2015, 289ra286.
32. [32] Timmerman, L.A., Holton, T., Yuneva, M., Louie, R.J., Padro, M., Daemen, A., et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 24 (2013), 450–465.
33. [33] Dai, L., Cao, Y., Chen, Y., Parsons, C., Qin, Z., Targeting xCT, a cystine-glutamate transporter induces apoptosis and tumor regression for KSHV/HIV-associated lymphoma. J. Hematol. Oncol, 7, 2014, 30.
34. [34] Ishimoto, T., Nagano, O., Yae, T., Tamada, M., Motohara, T., Oshima, H., et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 19 (2011), 387–400.
35. [35] Takayama, T., Kubo, T., Morikawa, A., Morita, T., Nagano, O., Saya, H., Potential of sulfasalazine as a therapeutic sensitizer for CD44 splice variant 9-positive urogenital cancer. Med. Oncol, 33, 2016, 45.
36. [36] Meijer, C., Mulder, N.H., Hospers, G.A., Uges, D.R., de Vries, E.G., The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line. Br. J. Cancer 62 (1990), 72–77.
37. [37] Godwin, A.K., Meister, A., O'Dwyer, P.J., Huang, C.S., Hamilton, T.C., Anderson, M.E., High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. U.S.A. 89 (1992), 3070–3074.
38. [38] Okuno, S., Sato, H., Kuriyama-Matsumura, K., Tamba, M., Wang, H., Sohda, S., et al. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br. J. Cancer 88 (2003), 951–956.
39. [39] Yoshikawa, M., Tsuchihashi, K., Ishimoto, T., Yae, T., Motohara, T., Sugihara, E., et al. xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res 73 (2013), 1855–1866.
40. [40] Han, H.Y., Kim, H., Jeong, S.H., Lim, D.S., Ryu, M.H., Sulfasalazine induces autophagic cell death in oral cancer cells via Akt and ERK pathways. Asian Pac. J. Cancer Prev 15 (2014), 6939–6944.